As part of its strategy of focusing on drugs with long term patent protection in its core therapeutic areas, the Group will continue to evaluate opportunities to dispose of non-core assets. In 2007 the Group divested a portfolio of non-core products, including SOLARAZE and VANIQA, to Laboratorios Almirall ('Almirall') and sold EQUETRO and transferred post-approval study commitments to Validus Pharmaceuticals Inc.
Organization and Structure
During 2008, the Group undertook a court sanctioned Scheme of Arrangement, establishing Shire plc as the new Shire holding company.
In 2008, Shire acquired more than 98% of Jerini and is in the process of integrating Jerini into the Group: integration and acquisition related costs expensed during the year to December 31, 2008 totaled $10.3 million.
Business Highlights - Shire HGT announced on February 14, 2008, that the Group will invest approximately $400 million over four years through 2011 to expand its Lexington, Massachusetts campus, making Lexington the global center for HGTs research, development, and production. This will result in the creation of an estimated 680 additional full-time jobs over the next eight years, doubling the existing full time workforce. - On May 23, 2008 Shire plc (formerly known as Shire Limited), a public company with its primary listing on the London Stock Exchange (secondary listing on NASDAQ), incorporated in Jersey and tax resident in the Republic of Ireland, became the holding company of the Shire group, pursuant to a scheme of arrangement under Sections 895 to 899 of the United Kingdom Companies Act 2006 (the 'Scheme'). The Scheme was approved by the High Court of England and Wales and the shareholders of Shire plc, the former holding company of the Shire group. The introduction of a new holding compan
|SOURCE Shire Plc|
Copyright©2009 PR Newswire.
All rights reserved